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Abstract: Vibrio cholerae ATP-binding cassette transporter VcaM (V. cholerae ABC multidrug resistance
pump) has previously been shown to confer resistance to a variety of medically important drugs.
In this study, we set to analyse its properties both in vitro in detergent-solubilised state and in vivo
to differentiate its dependency on auxiliary proteins for its function. We report the first detailed
kinetic parameters of purified VcaM and the rate of phosphate (Pi) production. To determine the
possible functional dependencies of VcaM on the tripartite efflux pumps we then utilized different
E. coli strains lacking the principal secondary transporter AcrB (Acriflavine resistance protein), as well
as cells lacking the outer membrane factor (OMF) TolC (Tolerance to colicins). Consistent with the
ATPase function of VcaM we found it to be susceptible to sodium orthovanadate (NaOV), however,
we also found a clear dependency of VcaM function on TolC. Inhibitors targeting secondary active
transporters had no effects on either VcaM-conferred resistance or Hoechst 33342 accumulation,
suggesting that VcaM might be capable of engaging with the TolC-channel without periplasmic
mediation by additional transporters. Our findings are indicative of VcaM being capable of a one-step
substrate translocation from cytosol to extracellular space utilising the TolC-channel, making it the
only multidrug ABC-transporter outside of the MacB-family with demonstrable TolC-dependency.
Keywords: ATP-binding cassette transporter; VcaM; V. cholerae; TolC; multidrug efflux pumps
1. Introduction
Vibrio cholerae is a Gram-negative non-invasive enteric pathogen and the causative agent of
cholera—a severe diarrheal disease [1]. The proliferation of V. cholerae has been linked to plankton
density in water, the chitin of which can be used by V. cholerae as carbon and nitrogen sources [2].
V. cholerae has over 200 serotypes based on the cell-surface O-antigens, with so far, only O1 and O139
serotypes being identified as cause of epidemic cholera. Cholera has been categorized as one of the
re-emerging infections threatening many developing countries. While fluid replacement remains the
most important component of therapy, antibiotic treatment with tetracyclines, fluoroquinolones and
macrolides is central for limiting morbidity and mortality by inhibition of the growth of V. cholerae [3,4].
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V. cholerae utilises a formidable array of antibiotic resistance mechanisms including chromosomal
mutations, exchange of conjugative plasmids, self-transmissible chromosomally integrating
SXT-elements and multidrug transporters [4,5]. V. cholerae has been shown to develop resistance
to a broad range of frontline antibiotics including tetracycline, macrolides and fluoroquinolones [4].
Multidrug efflux pumps and transporters provide a first line of defence allowing development of
additional resistance mechanisms and, thus, understanding their function is critical for addressing it.
To date, numerous multidrug transporters have been identified and investigated in V. cholerae, e.g.,
VexAB and VexCD from Resistance-Nodulation-Division (RND) family [6,7]. Colmer, et al. [8]
indicated that the VceB transporter, a homologue of E. coli EmrB, belonging to the Major Facilitator
Super family (MFS) forms a tripartite system with membrane protein VceA and an outer membrane
factor (OMF) VceC [9]. The Multidrug And Toxic Compound Extrusion (MATE) family transporters
VcmA [10], NorM [11] and VcrM [12], driven by electrochemical potential of Na+, have been reported.
In addition, Huda, et al. [13] reported the primary active ATP-binding cassette (ABC) transporter
VcaM (GenBank Q93GU0) conferring drug resistance. Several different groups of active transporters
(including RND, ABC and the MFS families) require a member of TolC (OMF) family form functional
tripartite efflux pumps [14]. In E. coli, for example, TolC is shared amongst the RND-transporter-based
efflux pump AcrAB-TolC, ABC-transporter efflux pump MacAB and MFS-transporter based efflux
pump EmrAB all of which have been known to transport antimicrobial agents [15–18]. TolC family
members are present in most Gram-negative bacteria, such as MtrE (Multiple transferable resistance)
in Neisseria gonnorhoeae [19–21], TolC and VceC in V. cholerae, and OprM, OprJ and OprN (outer
membrane protein responsible for multiple-drug resistance) in P. aeruginosa [9,22,23]. TolC orhologues
in V. cholerae have been demonstrated to be essential for transport of bile acids, erythromycin, SDS and
other xenobiotic [22]. In addition, TolC orthologues are also involved in the ABC-transporter-based
type 1 secretion systems (T1SS) such as RTX (Repeats-in-toxins) toxin secretion in V. cholerae [24] and
the well characterized HlyBD-TolC in E.coli [25].
One puzzling issue with the potential tripartite pump which may contain VcaM in V. cholerae is
the lack of obvious periplasmic adapter proteins (PAPs) associated with the VcaM locus. However,
our sequence analysis (summarized in Table 1 below) reveals a number of potential candidate PAPs
which can plausibly associate with VcaM to form a functional pump based on their homology to
established tripartite pump systems in E. coli. As shown in Table 1, the PAPs AcrA and AcrD of E. coli
share a sequence identity of 36% with V. cholerae homolog MexC. E. coli MacA shared a sequence
identity of 38% with V. cholerae hemolysin D (HlyD), a PAP of the TISS (Type I secretion system). E. coli
EmrA and EmrK shared a sequence identity of 39 and 40% with V. cholerae VceA, respectively.
Table 1. E. coli PAP homologues in V. cholerae.
PAPs Inner Membrane Transporter PAP Homologues in V. cholera(SEQUENCE Identity %) Reference
RND family
AcrA AcrB; AcrD MexC, 36% [26,27]
AcrE AcrF MexC, 36% [28]
ABC family
MacA MacB Hemolysin D, 38% [29]
MFS family
EmrA EmrB VceA, 39% [17,30]
EmrK EmrY VceA, 40% [30,31]
PAPs, periplasmic asapter proteins; RND, Resistance-Nodulation-Division; MFS, Major Facilitator
Super family; AcrA (Genbank NP_414996); AcrB (Genbank NP_414995); AcrD (Genbank NP_416965) MexC
(Genbank WP_001131865.1); AcrE (Genbank NP_417731); AcrF (Genbank NP_417732); MacA (Genbank NP_415399);
MacB (Genbank NP_415400); Hemolysin D (Genbank WP_000083084.1); EmrA (Genbank NP_417170); EmrB
(Genbank NP_417171); VceA (Genbank NP_231053); EmrK (Genbank NP_416869); EmrY (Genbank NP_416868).
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VcaM has been reported to have an effect on drug susceptibility and dye accumulation in vivo [13],
but so far it has not been overexpressed and purified in a detergent-solubilized state. Thus, the kinetic
parameters of VcaM have not been determined in vitro in detail. In this study, we present the first
direct kinetic parameters of VcaM from V. cholerae based on an in vitro detergent-solubilised form
and, by using a range of different E. coli genetic knock-out strains, demonstrate for the first time its
functional dependency in vivo on the OMF TolC. Furthermore, our data clearly demonstrates that
VcaM is not dependent on secondary RND transporters for its efflux function suggesting that it is
capable of directly bridging the TolC channel without the substrate being released as a periplasmic
transport intermediate.
2. Results and Discussion
2.1. Overexpression and Purification of VcaM in E. coli
In order to determine the kinetic parameters of the putative ATPase transporter VcaM from
V. cholerae (GenBank Q93GU0), the vcaM gene was amplified and cloned onto pET21a vector to
generate the plasmid pET21a-vcaM. The plasmid was then transformed into E. coli C43 (DE3) cells.
VcaM expression was induced with 0.2 mM IPTG, and purified by using the nickel affinity column.
The overexpression of VcaM in C43 (DE3) was confirmed by using SDS-PAGE and Western blot
(Figure 1).
Figure 1. The (A) Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
(B) Western blot of V. cholerae VcaM. The 10% SDS-PAGE showed the purified fraction of monomeric
VcaM (right lane, between 55 and 72 kDa) and dimeric VcaM (right lane, slightly below 130 kDa).
The Western blot was performed with a mouse anti-histidine tag primary antibody and goat anti-mouse
IgG-AP conjugate as the second antibody.
SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) revealed major protein
bands with the apparent molecular weight of approx 65 kDa and 130 kDa respectively (Figure 1).
The band at 65 kDa molecular weight was confirmed to be the VcaM protein and is consistent with
the predicted size of 69.8 kDa of the vcaM gene product. The protein band at 130 kDa is consistent
with a dimeric form of the VcaM, which is typical of the ABC-transporters with split NBD-domains
(e.g., previously reported MacB exhibits similar behaviour [18,32]). The protein band of dimeric VcaM
was resistant to boiling in the presence of reducing agent, suggesting that the VcaM dimers might have
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been stabilized by non-disulphide covalent bonds. Consistently, Western blot using HisProbe confirms
this interpretation (Figure 1).
2.2. Kinetic Parameters of ATP Hydrolysis by VcaM
Well-characterised ABC transporters, such as MacB from E. coli, displayed a basal ATPase
activity in detergent micelles. VcaM has been reported to have an effect on the drug susceptibility
and dye accumulation in vivo [13], but the kinetic parameters of VcaM have not been determined
in vitro in detail. The kinetic parameters of VcaM in its detergent-solubilized state were measured
using ATPase assay based on a Malachite green system, which is based on the quantification of a
green-coloured complex formed as a result of inorganic phosphate reacting with Malachite Green
and ammonium molybdate. For that, we investigated the hydrolysis of different concentrations
of ATP by the purified VcaM (Figure 2A). The results show that ATP hydrolysis increases in a
concentration-dependent manner. From the plots, we derived the kinetic parameters of purified
VcaM from affinity chromatography which gave a Vmax of 58 nmol/mg−1 min−1, a Km value of 852
µM and a Kcat of 0.07 s−1 in a steady state rate of Pi production (Figure 2B), which is the first time that
the detailed kinetic parameters of detergent-solubilized VcaM have been reported.
Figure 2. The Adenosine triphosphatase (ATPase) activity of VcaM. (A) Pi generation by VcaM on
various concentration of ATP (B) The steady-state rate of Pi production by VcaM. The ATPase activity
was measured by malachite green assay using 0.5 mM VcaM in detergent-solubilised state.
This level of activity is comparable to the previously reported ATPase activity of purified MacB,
which has a Km value of 910 µM and a Kcat of 0.17 s−1 [32]. It was previously reported that Sav1866
from Staphylococcus aureus exhibited a Vmax of 63 nmol Pi/mg−1min−1 although the Km value for ATP
was not determined [33], and the McjD from Escherichia coli gave a Km of 169.3 ± 6.7 µM and a Vmax of
44.4 ± 0.5 nmol min−1 mg protein−1 [34].
2.3. VcaM Efflux in E. coli Depends on the OMF TolC.
The OMF TolC is an essential part of many tripartite efflux pumps, but to date, it has not been
shown to associate directly with any other ABC-transporter-based efflux pumps apart from the
highly-specialised MacB-family [35]. Indeed, the majority of secondary and ABC-transporters appear
to pump their cargoes into the periplasmic space, from where they are picked up by broad-specificity
RND transporters such as AcrB and siphoned out of the cell using the OMF TolC as a universal
duct [36]. For eample, in Salmonella, at least nine different efflux systems converge on TolC [37].
Based on these observations, in orderto analyse the potential mechanism of the drug efflux by VcaM
we chose to use the drug-sensitive E. coli strains Kam3 (∆acrB) and TG1 cells (∆tolC) in efflux studies
to allow us to decouple the two stages of drug transport described above and to establish whether the
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substrate is being released into the periplasm to be picked up by RND-pumps or proceeds directly
to TolC. We reasoned that if VcaM operates in an RND-dependent fashion we should see a prominent
activity contribution in a Hoechst 33342 accumulation assay, a dye which becomes greatly fluorescent
when it binds to DNA and lipid membranes. We used time-resolved Hoechst H33342 fluorescence to
monitor whether VcaM is (a) able to provide increased efflux function in a heterologous expression
system, (b) requires secondary RND transporters for it and, (c) whether its function is dependent on
the duct of the OMF TolC to efflux substrates. Although effective efflux by heterologously expressed
VcaM has been reported already [13], we validated its activity in cells lacking the secondary transporter
AcrB [Kam3 cells (∆acrB)] in the presence and absence of the ATPase inhibitor sodium orthovanadate
(NaOV) (Figure 3). This allows for a higher sensitivity of the assay as it removes the function of the
AcrB, which is the dominant efflux pump in E. coli often masking the activity of the minor transporters.
First, in order to confirm that the efflux depends on the ATPase activity of VcaM,
the accumulation of H33342 was performed in the Kam3 cells (∆acrB) harbouring plasmid
encoding VcaM (Kam3-pQE-VcaM). The efflux of H33342 was higher in cells expressing VcaM
than the cells harbouring control plasmid, confirming that VcaM is active and capable of H33342
substrate expulsion. Accordingly, addition of NaOV to cells expressing VcaM caused a notable increase
of H33342 accumulation. Addition of vanadate, a phosphate analogue, in the presence of ATP, resulted
in stable trapping of MgADP·Vi in one of the ATPase catalytic sites [38], and this data indicated that
the activity of VcaM was responsible for the majority of H33342 efflux (Figure 3).
The fact that the VcaM seems to be readily providing efflux/resistance when heterologously
expressed may appear strange if we consider that the remaining components of the putative efflux
pump are missing. One possible explanation for the observed effect is that the periplasmic adaptor
proteins (PAPs) of the E. coli are able to pair effectively with VcaM providing at least some level
of compatibility with TolC. Indeed, the TolC from Vibrio vulnificus has been reported to effectively
complement the delta tolC in E. coli suggesting a high level of compatibility of these efflux systems [39].
Furthermore, the analysis of the TolC sequences from V. cholerae demonstrate that in particular,
VC2436 protein which appears to be the closest TolC homologue in Vibrio cholerae O1 shows 47%
sequence identity to TolC of E. coli K12 (as determined by the SIM expasy server) and displays high
level of similarity in the region of periplasmic helical turns which are supposed to be involved in
PAP-binding [22].
Figure 3. Drug accumulation of H33342 in E. coli Kam3 overexpressing VcaM in the presence of ABC
transporter inhibitor NaOV. H33342 was incubated for 38 min in the presence of 40 µg/mL NaOV.
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2.4. The Efflux of H33342 Conferred by VcaM/TolC is Independent of Secondary Active Transporters in E. coli
To establish whether there is a one-step translocation of VcaM and the OMF TolC, possibly with the
help of PAPs, or whether the efflux may be mediated by a secondary transporter different from AcrB as
a two-step translocation (e.g., AcrD, AcrF or MdtABC) [40], we performed efflux assays in the presence
of the RND-pump-specific inhibitor PAβN (phenylalanine-arginine beta-naphthylamide) and general
secondary-transporter inhibitor CCCP (Carbonyl cyanide m-chlorophenylhydrazine) as follows. It was
previously reported that the RND transporter AcrAB-TolC complex and its homologue MexAB-OprM
may capture substrates from the periplasm, because carbenicillin, which does not diffuse across the
cell membrane, was effluxed by the AcrAB-TolC complex [41]. In addition, the RND transporter AcrD
can also capture aminoglycosides from the periplasmic space to extrude them into the extracellular
space in intact cells [26].
In order to understand whether the H33342 efflux by VcaM/TolC was mediated by secondary
active efflux pump systems (two step translocation), the accumulation of H33342 in the Kam3 cells
(∆acrB) harbouring a plasmid encoding VcaM (Kam3-pQE-VcaM) in the presence and absence of the
RND-pump-specific inhibitor PAβN (Figure 4) and general secondary active transporters inhibitor
CCCP (Figure 5) were tested.
Figure 4. Drug accumulation of H33342 in E. coli Kam3 overexpressing VcaM in the presence of
RND-transporter inhibitor PAβN. H33342 was incubated for 38 min in the presence of 20 µg/mL PAβN.
The accumulation of H33342 was lower in the cells expressing VcaM than the cells harbouring
empty plasmid. CCCP is a protonophore, which causes dissipation of the membrane potential, thus,
affecting all the secondary transporter-dependent efflux [42], and and the peptidomimetic compound
PAβN has been shown to be a RND-pump inhibitor [43]. Addition of PAβN and CCCP to the cells
expressing VcaM did not abolish H33342 efflux (p < 0.05), suggesting that the TolC-dependent efflux of
H33342 by VcaM does not require secondary active transporters, such as AcrD and YhiV (MdtF) [44,45].
Thus, the translocation of H33342 by VcaM/TolC might be a one-step translocation from
cytoplasm to extracellular space.
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Figure 5. Drug accumulation of H33342 in E. coli Kam3 overexpressing VcaM in the presence of
membrane decoupling secondary transporter inhibitor CCCP. H33342 was incubated for 38 min in the
presence of 20 µg/mL CCCP.
2.5. Dependence on OMF TolC
Our previous data indicated that secondary transporters are not required for the function of
VcaM, and we, therefore, wanted to confirm that the OMF actually is directly responsible for the effects
observed in its heterologous expression. Consistent with the TolC-dependence of the VcaM efflux,
the accumulation of H33342 was high (high fluorescence) in the TG1 (∆tolC) cells harbouring empty
plasmid and the plasmid encoding VcaM (TG1-pQE-VcaM), indicating VcaM required TolC for H33342
efflux (Figure 6).
Importantly, and consistent with the interpretation that VcaM is capable of directly engaging
with the OMF, the Kam3 cells (∆acrB) harbouring the plasmid encoding VcaM had lower H33342
accumulation as compared the Kam3 cells harbouring empty control plasmid, indicating the
simultaneous presence of both VcaM and TolC was sufficient (p < 0.05) to confer efflux of the substrate
dye H33342 (Figure 6).
The disk diffusion assay was performed in the cells lacking the outer membrane factor TolC [E. coli
BW25113 cells (∆tolC) (DE3)] harbouring control plasmid, the plasmid encoding VcaM, the plasmid
encoding TolC, and the plasmid encoding both VcaM and TolC (Figure 7). The diameter of zone
of inhibition for the erythromycin (10 µM) disk was measured, the inhibition zone of the BW25113
cells expressing both VcaM and TolC (12.1 ± 0.9 mm) was smaller than the cells harbouring plasmid
encoding VcaM (22 ± 1.4 mm) or TolC alone (14 ± 2.1 mm), suggesting that VcaM conferred a high
level of resistance to erythromycin when co-expressed with TolC. This data is consistent with our
previous result on the efflux of H33342 by VcaM, and its dependency on TolC (Figure 7).
It has been previously reported that TolC was required for the function of ABC-type macrolide
transporter MacB, RND transporter AcrB and MFS transporter EmrB, which cooperate with PAPs
MacA, AcrA and EmrA and outer membrane channel TolC to form a tripartite efflux system to enhance
the resistance of antibiotics [40,46,47]. Moreover, a previous report demonstrated that TolC from E. coli
could replace VceC from V. cholerae to form a functional tripartite efflux system with VceAB-TolC in
E. coli cells [48], displaying a high degree of OMF-PAP promiscuity.
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Figure 6. Drug accumulation of H33342 in drug sensitive strain E. coli Kam3 and TG1
overexpressing VcaM.
Figure 7. Representative disk diffusion assay results demonstrating the VcaM dependency on TolC.
10 µg impregnated erythromycin disk was placed and incubated at 37 ◦C overnight.
2.6. Periplasmic Adapter Proteins Might be Needed for V. cholerae VcaM to Provide TolC-Dependent Efflux
The VcaM topology prediction [49] indicated that it contains six transmembrane helices (Figure S1)
and lacks big periplasmic loops, suggesting it might need a PAP to bridge the OMF form for a one
step translocation. In the tripartite pump MacA/MacB/TolC which confers resistance to macrolides,
the macA gene (Genbank NC_000913, ECK0869) is located next to macB gene (Genbank NC_000913,
ECK0870) on the E. coli K12 chromosome (Genbank NC_000913) [18]. Intriguingly, there is no PAP
sequence located next to the vcaM gene (Genbank NC_002506.1, VCA0996) in V. cholerae.
Our efflux and disk diffusion assay results indicated that VcaM conferred efflux with the help
of E. coli TolC, possibly mediated by a PAP in E. coli based on their close homology and potential
cross-reactivity. Such interpretation is reinforced by previous reports of cross-reactivity and functional
substitution between TolC and VceC [48]. Thus, we surveyed the possible drug efflux-associated PAP
that might combine with VcaM in E. coli along with their homologues in V. cholerae (see Table 1 above).
Moreover, E. coli AcrA, AcrE, MacA and EmrK and V. cholerae MexC and VceA share a common
structural motif RxxxLxxxxxxS (RLS or RLT) (x stands for any residues) (Figure 8) [50,51], which
is believed to play an important role in the interaction with the TolC aperture and can provide an
explanation for such a promiscuity of interaction between heterologous PAPs and OMFs. Our data
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suggests that the recombinant V. cholerae VcaM is able to interact with the endogenous E. coli TolC and
PAPs for one-step translocation of substrates, which might reflect the existence of a similar mechanism
in V. cholerae, however, further work is required to determine the exact PAP with which it engages
in situ.
Figure 8. Sequence alignment of the PAPs in E. coli and V. cholerae. Ec AcrA (Genbank NP_414996);
Ec AcrE (Genbank NP_417731); Ec MacA (Genbank NP_415399); Ec EmrA (Genbank NP_417170); Vc
MexC (Genbank WP_001131865.1); Vc VceA (Genbank NP_231053).
While ABC-transporters of the HlyB family are well-known to associate with TolC channels
forming part of the tripartite Type I secretion systems (T1SS) [51,52], the only ABC-drug transporter
with established TolC dependency is the MacB. MacB, however, presents a unique architecture amongst
the ABC transporters [29,35,53] by possessing a pronounced periplasmic domain with structural
similarities to the larger RND transporters [29,54], allowing it to assemble PAP proteins containing
membrane-proximal domains (MPDs) and recruit TolC [55]. Notably, no classical 6TM-spanning
dimeric ABC-transporters that seem to share the closest similarity with VcaM i.e., Sav1866 or MsbA-like
families have been demonstrated to be able to associate with TolC to date. It is, however, conceivable
that the arrangement within a putative tripartite system containing VcaM is similar to the one
within the T1SS-associated transporters (which also share the predicted VcaM topology of being
dimers with 6TM-per subunit) or MFS-transporter-based assemblies [52,56]. Both of these require
PAP-proteins lacking MPDs to effectively seal the tripartite assembly, which are not readily identifiable
in the Vibrio genome. As we have discussed above, cross-reactivity of VcaM with endogenous PAPs
within E. coli could possibly provide an explanation for the TolC-dependent function observed in a
heterologous expression background. Indeed, a sequence analysis of the Vibrio genome reveals at least
five TolC orthologues which demonstrates a wide variety of potential pairings for the VcaM, which
some of these OMFs exhibiting high-level of similarity (over 70%) with the E.coli TolC [22].
While future research is required to elucidate the exact mechanism by which the VcaM-family of
ABC-transporters engage TolC, our clear demonstration of its TolC-dependency is both important and
intriguing, as it makes it the only currently known member of the ABC-family lacking pronounced
periplasmic domains that is capable of recruiting TolC while having an established drug-efflux function.
3. Materials and Methods
3.1. Bacterial Strains, Media and Chemicals
The vcaM gene was from V. cholerae strain CVD101 (CT–A–, CT–B+ deletion derivative of classical
biotype Ogawa serotype 395) chromosomal DNA [57]. Escherichia coli C43 (DE3) were used for
protein expression, Escherichia coli Kam3 (DE3) which is the acrB deletion strain and E. coli TG1 ∆tolC
(a derivative of TG1 that lacks tolC) were used in drug accumulation assay [58]. E. coli BW25113
∆tolC was converted to (DE3) by DE3 lysogenization (Novagen) and used for disk diffusion assays.
The bacteria were grown in Luria–Bertani broth (LB), 2XYT medium broth and Mueller-Hinton broth
(MH broth). The ampicillin (100 µg/mL) was used in the experiment.
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3.2. Cloning of VcaM
vcaM gene was cloned from the V. cholerae CVD101 chromosome by using PCR method. The vcaM
gene amplified by using primers 5′-GGGGGGCATATGTTTAAGCTATTTGAAGGTTTCACCGAC-3′
and 5′-TTTTTTCTCGAGTGCCAGTATGGCTTCTTCTAC-3′ which was digested with NdeI and XhoI
restriction enzymes and inserted onto pET21a vector at the NdeI-XhoI site. The vcaM gene was amplified
using the primers, the PCR products ere digested with BamI and PstI restriction enzymes and inserted
onto pQE100 vector at the BamI-PstI site. The pET21a plasmid encoding VacM was transform into E. coli
C43 (DE3) for protein overexpression and the pQE100 plasmid encoding VcaM was transform into
E. coli Kam3 and TG1 ∆tolC for drug susceptibility test. E. coli tolC was amplified from E. coli K12 strain
with forward and reverse primer 5′-AATAACATATGAAGAAATTGCTCCCCATTCTTATCGGC-3′
and 5′-AATAACTCGAGGTTACGGAAAGGGTTATGACCGTTACTGG-3′. The PCR products were
digested with NdeI and XhoI restriction enzymes and cloned into pET21a vector.
3.3. Expression and Purification
E. coli C43 (DE3) harboring plasmid encoding VcaM was cultivated at 37 ◦C, induced with
0.2 mM IPTG and overexpressed at 24 ◦C. The cells were collected by centrifugation and disrupted
by using French press. The pellet was removed by centrifugation, and the supernatant collected.
The supernatant was centrifuged at 43,000 rpm for 60 min to spin down the cell membranes, which
were collected and solubilised in 2% (v/v) Triton X-100 (BioShop, Burlington, ON, Canada). Detergent
solubilized VcaM was purified by using nickel affinity column (Hitrap chelating column, GE, Boston,
MA, USA) [59].
3.4. SDS-PAGE and Western Blot
Recombinant VcaM was resolved by SDS-PAGE to determine the efficiency of overexpression
and purification. As for western blot, VcaM samples were run using two SDS-PAGE gels by gel
electrophoresis in duplicate, applied as experimental gel and control gel. The proteins on the
experimental gel were transferred to a PVDF a PVDF (Polyvinydene fluoride) membrane using
semi-dry transfer (175 mA, 75 min). The membrane was washed three times with wash buffer (7.5 mM
K2HPO4, 150 mM NaCl, 0.05% (v/v) Tween 20, pH 7.4) and saturated with blocking buffer (wash buffer
containing 3% bovine serum albumin) at 4 ◦C. After three washes with wash buffer, the membrane was
incubated with primary antibody (mouse anti-histidine tag) for 1 h. The PVDF membrane was then
incubated with a goat anti-mouse IgG-AP (alkaline phosphatase) conjugate as a secondary antibody,
and the proteins were identified by using a colorimetric AP conjugate substrate kit (Bio-Rad, Hercules,
CA, USA) [18].
3.5. ATPase Activity Assay
The ATPase activity was measured by malachite green assay as described previously [60].
The reaction buffer containing 20 mM Tris (pH 7.4), 200 mM NaCl, 10 mM MgCl2, 0.2% Triton
X-100 and 0.5 µM VcaM was mixed with adenosine 5′-triphosphate disodium salt (ATP) and incubated
at 37 ◦C. 5 mM MgCl2 was added to initiate ATPase activity, and sample was taken from the reaction
mixture to mix with EDTA (Ethylenediaminetetraacetic acid)to stop reaction on a time point from
0 to 10 min. Malachite green solution was added to each sample and an absorbance at 610 nm was
measured by a spectrophotometer [60]. The rate of ATP hydrolysis was measured as a function of the
ATP concentration and the data fitted to a sigmoidal equation using SigmaPlot (Systat Software Inc.
San Jose, CA, USA)).
3.6. Hoechst (H) 33342 Accumulation Assay
The H33342 bis-benzamide accumulation assay was carried out as previously described [61],
with the following modifications. The E. coli cells were grown to OD600 of 0.6 to 0.8 in MH broth
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and collected by centrifugation (5000 rpm, 5min and 4 ◦C). The cells were resuspended twice in PBS
buffer and diluted in PBS in a final OD600 of 0.6. The cell suspension was incubated in 96 well plate
with the filter-sterilized glucose to a final concentration of 25 mM at room temperature for 3 min.
The H33342 dye was added to a final concentration of 1 µM and the fluorescence was measured
over 38 min at excitation and emission wavelengths of 360 and 460 nm [61]. The efflux pump
inhibitors of NaOV, CCCP and PAβN was added to a final concentration of 40 µg/mL, 20 µg/mL and
20 µg/mL, respectively.
3.7. Disk Diffusion Assay
The disk diffusion assay was performed as previously described [62] with slight modification.
E. coli BW25113 ∆tolC cells were transformed with pACYC tolC from E. coli and or pET21a vcaM from
V. cholerae. The fresh transformants were grown in LB media supplemented with respective antibiotics
to an OD600 of 0.5, induced with 0.25 mM IPTG for 2 h at 37 ◦C. The induced cells were diluted
to an OD600 of 0.1 and spread the cells using sterile cotton swabs on Muller Hinton Agar (MHA)
incorporated with 0.25 mM IPTG. The plated were allowed to dry for a minute, 10 µg impregnated
Erythromycin disk (Oxoid) was placed and incubated at 37 ◦C overnight. Then the diameter of zone of
inhibition along the disk was measured and recorded. The assay was performed in triplicates.
3.8. Prediction of Transmembrane Regions
The transmembrane regions of VcaM was predicted by using TMHMM server (Available online:
http://www.cbs.dtu.dk/services/TMHMM/) [49].
3.9. Protein Sequence Alignments
The protein sequences of MexC (GenBank WP_001131865.1) and VceA (GenBank NP_231053)
from V. cholerae, AcrA (GenBank NP_414996)/AcrE (GenBank NP_417731)/MacA (GenBank
NP_415399)/EmrA (GenBank NP_417170) and EmrK (GenBank D78168) from E. coli were
obtained from the National Center for Biotechnology Information (NCBI, available online:
www.ncbi.nlm.nih.gov), and the sequences were aligned by using Clustal Omega multiple sequence
alignment (Hinxton, Cambridge, UK) [63].
3.10. Statistical Analysis
Data were statistically analyzed using SPSS Version 12.0 (SPSS Inc., Chicago, IL, USA). One-way
analysis of variance (ANOVA) was used to determine the statistical differences between the sample
means, with the level of significance set at p < 0.05. Multiple comparisons of the means were conducted
using the Tukey test. All data are expressed as mean ± SD.
4. Conclusions
In this study, we confirmed VcaM as a bona-fide drug ABC-transporter by giving the detailed
kinetic parameters of ATP hydrolysis, and reported VcaM as the only multidrug ABC-transporter
outside of the MacB-family with demonstrable TolC-dependency. A TolC-dependent efflux by VcaM
was observed in dye accumulation and disk diffusion assays. The secondary active transporter
inhibitors, PAβN and CCCP, did not retard the efflux of H33342 conferred by VcaM, indicating that
VcaM might confer a one-step translocation in a TolC-dependent manner. A periplasmic adapter
protein could be involved to link VcaM and TolC in the construction of a tripartite pump for substrate
translocation, although future research is clearly required to elucidate the exact mechanism.
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/19/4/1000
/s1.
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